TransMedics Group (NASDAQ:TMDX) Shares Gap Up - Here's What Happened

Key Points

• TransMedics Group saw a significant uptick in share price, gapping up from $105.58 to $113.95, before settling at $108.18 with a trading volume of 706,661 shares.
• Analysts have varied opinions on the stock, with Morgan Stanley raising its price target from $115.00 to $123.00 and Oppenheimer increasing theirs from $130.00 to $150.00, while Wall Street Zen downgraded it from "buy" to "hold."
• TransMedics reported strong quarterly earnings, with an EPS of $0.92 surpassing estimates and a revenue increase of 37.7% year-over-year, leading to an average price target set at $122.11 by analysts.

Shares of TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) gapped up before the market opened on Tuesday . The stock had previously closed at $105.58, but opened at $113.95. TransMedics Group shares last traded at $108.18, with a volume of 706,661 shares trading hands.

Analysts Set New Price Targets

Several research firms recently weighed in on TMDX. Wall Street Zen lowered shares of TransMedics Group from a "buy" rating to a "hold" rating in a research report on Saturday, August 30th. Morgan Stanley increased their price target on shares of TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a research report on Friday, August 1st. Oppenheimer raised their price target on TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 17th. Stifel Nicolaus began coverage on TransMedics Group in a research report on Thursday, September 4th. They issued a "hold" rating and a $115.00 price target for the company. Finally, Canaccord Genuity Group boosted their price target on TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a research note on Tuesday, July 15th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $122.11.

TransMedics Group Stock Performance

The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.17 and a current ratio of 9.86. The firm's 50 day simple moving average is $117.50 and its 200 day simple moving average is $104.70. The firm has a market capitalization of $3.71 billion, a price-to-earnings ratio of 56.06 and a beta of 2.18.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.48 by $0.44. The business had revenue of $157.37 million during the quarter, compared to analysts' expectations of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The business's quarterly revenue was up 37.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.35 EPS. TransMedics Group has set its FY 2025 guidance at EPS. Sell-side analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Amalgamated Bank lifted its position in TransMedics Group by 0.8% in the second quarter. Amalgamated Bank now owns 9,586 shares of the company's stock valued at $1,285,000 after buying an additional 80 shares during the last quarter. Canada Pension Plan Investment Board increased its stake in shares of TransMedics Group by 2.9% during the second quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company's stock worth $482,000 after buying an additional 100 shares during the period. Smartleaf Asset Management LLC boosted its holdings in TransMedics Group by 24.5% in the second quarter. Smartleaf Asset Management LLC now owns 548 shares of the company's stock valued at $72,000 after purchasing an additional 108 shares in the last quarter. Ameritas Investment Partners Inc. boosted its holdings in TransMedics Group by 4.4% in the second quarter. Ameritas Investment Partners Inc. now owns 3,394 shares of the company's stock valued at $455,000 after purchasing an additional 142 shares in the last quarter. Finally, Franklin Resources Inc. boosted its holdings in TransMedics Group by 1.0% in the second quarter. Franklin Resources Inc. now owns 14,842 shares of the company's stock valued at $1,989,000 after purchasing an additional 148 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.